Endo Pharmaceuticals Inc et al v. Watson Laboratories Inc, No. 2:13-cv-00192 (E.D. Tex. June 23, 2014)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Before the Court are Plaintiffs’ Endo Pharmaceutical Inc. and Strakan International S.á r.l. Opening Claim Construction Brief (Dkt. No. 58), Defendant’s Watson Laboratories, Inc.’s Responsive Claim Construction Brief (Dkt. No. 62), and Plaintiffs’ reply (Dkt. No. 63), concerning U.S. Patent No. 6,319,913 (“the ‘913 patent). The Court held a hearing on June 6, 2014. 2 I. BACKGROUND This case concerns Defendant’s alleged infringement of the ‘913 patent, as well as U.S. Patent No.